COMMUNIQUÉS West-GlobeNewswire

Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company
14/09/2026
Cellectis to advance two lead in vivo programs .HEAL-101 and .HEAL-201 in severe dyslipidemias with preliminary Phase 1 data planned in H2 2027 and H1 2028, respectively Transformation supported by continuing existing [...]
Cellectis annonce sa transformation stratégique en société d'édition du génome in vivo
14/09/2026
Cellectis fait progresser ses deux programmes in vivo phares, .HEAL-101 et .HEAL-201 dans les dyslipidémies sévères, avec des données préliminaires de phase 1 attendues respectivement au second semestre 2027 et au [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
14/09/2026
COPENHAGEN, Denmark, September 14, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an [...]
Avacta Appoints Mats Blom to the Board of Directors as Chair of Audit Committee
14/09/2026
LONDON and PHILADELPHIA, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION ® , a tumor-activated oncology delivery platform, today [...]
NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer
14/09/2026
All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was deemed feasible One- [...]
NANOBIOTIX annonce les résultats complets de la phase 1 pour JNJ-1900 (NBTXR3) dans le cancer du poumon non à petites cellules inopérable et récurrent
14/09/2026
L’ensemble des 24 patients a été traité sans toxicité limitant la dose, sans événement indésirable de grade 3 ou supérieur liés à JNJ-1900 (NBTXR3) ou à la procédure d’injection, et l’injection intratumorale a été jugée [...]
Basilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba® (isavuconazole) in pediatric patients
14/09/2026
Allschwil, Switzerland, September 14, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal [...]
Beverly Wilshire Aesthetics Beverly Hills Medical Spa Announces Global Rebrand, Expanding Botox, Dermal Fillers, and Morpheus8 Services
14/09/2026
BEVERLY HILLS, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Beverly Wilshire Aesthetics Medical Spa Beverly Hills is a leading full-service medical spa serving patients throughout Beverly Hills and the Los Angeles [...]
MemoHoney Launch Advanced Brain Memory Support Capsules 2026 in USA: Read Memohoney Supplement Facts, Benefits and Ingredients Highlights.
13/09/2026
MemoHoney 2026 Announces a natural formula in the USA, designed to support brain health, memory and focus. Explore Memo Honey supplement facts, ingredients and key benefits. New York, Sept. 13, 2026 (GLOBE NEWSWIRE) -- [...]
Zenbody RX Launches Telehealth Platform Built Around Personalized, Clinician-Guided GLP-1 Care
13/09/2026
The platform combines online access, individualized treatment, home delivery, and continued patient support in one connected care experience Winter Park, FL, Sept. 12, 2026 (GLOBE NEWSWIRE) -- Zenbody RX has launched [...]
Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer
13/09/2026
Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death by 54% and disease progression by 71%, while achieving [...]
Impact BioMedical Inc (NYSE American: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Ltd. (previously Dr. Ashley’s Ltd.)
11/09/2026
HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (the “ Company ”) today announced that the Company's Board of Directors has approved a 1 for 12.62 reverse stock split of the Company's issued and [...]
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11/09/2026
CAMBRIDGE, Mass., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA ® ) platform to develop a new [...]
Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity
11/09/2026
Virtual Webcast to be Held Monday, September 14, 2026, at 8:00 AM EDT NORWOOD, Mass., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on [...]
Erica Zarkovich, Chief Market and Partnerships Officer, Named One of Canada’s Most Powerful Women: Top 100
11/09/2026
Toronto, Canada, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Erica Zar kovich, Chief Market and Partnerships Officer, has been named one of Canada’s Most Powerful Women: Top 100 by WXN Media in the CN Executive Leaders category [...]
The GLP-1 Boom Is Bypassing Latino Patients; Bilingual Telehealth Clinic Sol y Vida Launches to Change That
11/09/2026
— Latino-founded, LegitScript-certified clinic opens for Hispanic Heritage Month with licensed clinicians, published prices and care in Spanish — “recetado, no comprado” — LOS ANGELES, CA, Sept. 12, 2026 (GLOBE NEWSWIRE [...]
Interim results for the six months ended June 30, 2026
11/09/2026
September 11, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2026 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company [...]
Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update
11/09/2026
NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving [...]
Cellectis organise une conférence téléphonique et un webcast le 14 septembre pour présenter un point d’activité
11/09/2026
NEW YORK, 11 sept. 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth : ALCLS ; Nasdaq : CLLS), société de biotechnologie de stade clinique, qui utilise sa plateforme pionnière d'édition de génome pour développer des [...]

Pages